Clinical Trials in Depression Reveal New R&D Priorities in 2026

Clinical trials in depression now encompass a range of treatment approaches, much wider than the traditional antidepressant pipeline of the past.

Ahead of World Mental Health Day on 10 October, a new analysis of U.S. and European trial registries offers a rare view of how interventions, sponsors, trial phases, and biological data have shifted since 1987.

Image

A 37-Year View of Depression Trials

Clinical trials in depression have generated a vast evidence base, but the data is not equally useful across studies.

A new analysis of 8,853 trials shows how treatment research has shifted from established antidepressants towards newer approaches while exposing gaps that could slow more personalised care.

The analysis brings together depression-related records from the U.S. ClinicalTrials.gov and the EU Clinical Trials Register registered from 1987 through 2024. About 86% came from the U.S.-based Aggregate Analysis of ClinicalTrials.gov (AACT) resource, while the remainder came from the European registry.

But while depression research has produced thousands of clinical trials since the late 1980s, the sheer volume of studies does not automatically create a clearer path to better treatment.

This analysis shows how much evidence already exists across pharmacological, behavioural, device-enabled, and other interventions. It also creates an opportunity to extract more value from research that has already been conducted.

Depression research is not a single therapeutic market. Trials have examined medicines alongside behavioural interventions, devices, and digital approaches.

Of the full dataset, 3,659 trials, or 41%, involved a drug intervention. Within that group, 1,160 trials tested antidepressants.

The numbers also expose a long-standing Clinical Development problem. Antidepressants can help many patients, but response is inconsistent, and remission remains difficult to achieve.

Only about one-third of patients reach remission during an antidepressant treatment period, reinforcing the need for better ways to match therapies to patients.

The Depression Treatment Landscape Is Shifting

Drugs represented the largest intervention category in the dataset. There were 3,659 trials involving a drug intervention, equivalent to 41% of all identified studies.

Antidepressants accounted for 1,160 of those drug trials. Selective serotonin reuptake inhibitors (SSRIs) dominated this group, with 899 trials. Escitalopram was the most frequently studied individual drug, appearing in 322 trials.

The historical pattern is more revealing than the totals.

SSRI trials reached their highest level around 2009. After 2015, research involving NMDA receptor antagonists such as ketamine increased sharply. The change reflects a broader expansion of interest in mechanisms beyond conventional monoamine-based treatment.

Image

The trial landscape is also wider than drug development alone.

Behavioural interventions appeared in 3,291 trials, while device-enabled or mobile interventions appeared in 986. Some studies combined different intervention types, creating a more complex picture of how depression is being treated and studied.

Sponsor patterns provide another point of strategic evidence. Academic and public-sector organisations accounted for 76.1% of all trials. Healthcare industry sponsors represented 18.4%.

Among drug-intervention trials, however, industry involvement rose to 38.5%. For trials involving drugs specifically classified as depression treatments, healthcare industry sponsorship accounted for 29.8%.

This matters when assessing the development pipeline. Industry involvement is concentrated more heavily in pharmacological research than in the overall depression trial ecosystem.

The shift towards newer mechanisms also creates new development questions. Ketamine and other NMDA-related approaches have changed expectations around how rapidly antidepressant effects might emerge and which biological pathways deserve greater attention.

Pharmatica’s Insights into psychedelic drug discovery highlights a similar movement towards alternative CNS mechanisms, receptor pharmacology, and neuroplasticity. The common thread is a move towards understanding depression as a more biologically diverse condition rather than a single treatment problem.

Read Reimagine AI-driven Drug Discovery with Pharma Superintelligence

Reimagine AI-driven Drug Discovery with Pharma Superintelligence

Explore how AI-driven drug discovery is evolving through Pharmaceutical Superintelligence and what your organisation can do to keep up.

Clinical Development Is Becoming More Data-Rich

One of the most valuable aspects of the study is its focus on information that may already exist inside completed or ongoing trials.

The researchers used natural language processing and semantic similarity scoring to identify records that were more likely to contain blood samples or genetic information.

This creates a bridge between conventional trial evidence and pharmacogenetic research.

Instead of treating each trial as a closed experiment, the dataset can help researchers identify studies that may contain biological material capable of supporting questions about treatment response.

This could be important, as personalised prescribing in depression remains difficult. Genetic factors appear to influence antidepressant response, but the effects are not straightforward, and useful predictors need large, well-characterised datasets.

Clinical trials are therefore best positioned as potential infrastructure for future research, not only as vehicles for testing an intervention.

And that has practical implications:

• Trial protocols can create future analytical value through better collection of biological and clinical data.
• Archived samples may support research questions that were not central to the original study.
• Consistent phenotype definitions could make datasets easier to combine across programmes.
• Better linkage between trial records and publications could improve the usability of evidence.

This is particularly relevant as pharma increases investment in biomarker-led development and precision psychiatry. Data collected today can influence the development decisions made years later.

That opportunity extends further than new medicines. The dataset contains substantial activity in behavioural interventions and device-enabled or mobile interventions, showing that depression development increasingly spans multiple therapeutic and delivery models.

Trial Data Quality Still Limits Strategic Use for Depression Medicines Development

The dataset also shows why volume should not be confused with evidence quality. Only 2,218 trials contained usable sample-size information. Of those, 1,281 had at least 100 participants, while 242 had at least 1,000.

Demographic coverage was also incomplete. The researchers could not produce a comprehensive analysis of participation by gender or race and ethnicity because the necessary information was not consistently available.

Definitions of depression severity and treatment-resistant depression also varied across studies.

These gaps have consequences. Patient stratification, external comparability, subgroup analysis, and pharmacogenetic research all depend on reliable, standardised information.

The analysis also highlights a registry problem. Trial records can be modified after registration, and registration practices have changed over time. The introduction of International Committee of Medical Journal Editors registration requirements in 2005 altered the information available across the historical record.

European registry records were also less detailed in some fields and lacked direct links to related publications.

For Clinical Development teams, trial data only becomes strategic intelligence when its context is preserved.

The value of a trial can is more than the primary endpoint. Sponsors need to consider how protocol design, metadata, biological samples, demographic detail, and publication linkage affect the future reuse of evidence.

That principle is increasingly important as pharma seeks to combine historical evidence with new computational approaches.

A larger dataset does not automatically produce a better model. Missing variables, inconsistent phenotypes, and differences in how trials were registered can introduce uncertainty before analysis even begins.

Read First Quarter 2026 State of Digital Health Funding

First Quarter 2026 State of Digital Health Funding

Digital health funding hit $7.4B in Q1 2026, the highest since Q2 2022. The CB Insights State of Digital Health report reveals where capital is concentrating and why it matters for pharma leaders.

Image

Pharmacogenetics Needs Better Trial Data

The analysis was done with a specific opportunity in mind: Identifying depression trials that could support pharmacogenetic research.

As discussed already, pharmacogenetics examines how genetic differences can influence response to medicines. In depression, this could eventually help move treatment decisions away from repeated trial and error towards more informed prescribing.

The potential is significant, but the evidence requirements are demanding.

Researchers need sufficiently large cohorts, reliable treatment-response measures, detailed patient characteristics, and biological material that can be linked to clinical outcomes.

These requirements are difficult to satisfy retrospectively when trial records were not designed for future genetic research.

The analysis researchers therefore used a language-based informatics approach to identify trial records that were more likely to contain biological samples or genetic information. Their scoring system prioritised records based on how closely their text matched predefined indicators.

This creates a useful bridge between Clinical Development data and modern computational research.

It also suggests a broader opportunity for sponsors. Trial data should be designed for reuse, not only for the primary endpoint.

Future studies could capture demographic, phenotypic, treatment, safety, biomarker, and genetic information in ways that make later analysis easier. This would increase the potential value of individual trials while supporting cross-study research.

The point is not to collect more data, but to collect better-connected data.

This principle applies to digital biomarkers, patient stratification, real-world evidence, disease subtyping, and emerging computational approaches to Clinical Development.

Image

How Clinical Development Teams Can Do Better Depression Clinical Trials

The depression trial landscape is extensive, but it remains fragmented.

Thousands of studies have tested medicines, psychological approaches, devices, and newer biological mechanisms, yet much of their underlying information is difficult to reuse.

The new analysis shows why future progress depends on the quality and structure of evidence as much as the number of trials conducted.

For sponsors, three priorities stand out:

• Design for reuse: Capture participant and treatment data in forms that support future research questions.
• Improve representation: Record demographic characteristics consistently enough to assess who benefits, who does not, and where evidence remains thin.
• Connect biology to outcomes: Build pathways for linking samples, biomarkers, genetics, exposure, safety, and treatment response.

What the Depression Trial Landscape Means for Clinical Development

The latest 2026 analysis provides a useful map of where depression Clinical Development has been, but its greater value is in showing where the next gains may come from.

First, mechanism diversity is increasing. The historical dominance of SSRIs is now accompanied by greater interest in NMDA receptor antagonists and other emerging approaches.

Secondally, Clinical Development is connected to biological data. Lastly, the research ecosystem remains heavily academic and public sector-led, although industry plays a much larger role in drug intervention trials.

The sponsor profile is notable. Academic and public organisations accounted for 76.1% of all trials, compared with 18.4% for healthcare industry sponsors.

Among drug-intervention trials, industry’s share rose to 38.5%. For trials involving drugs classified as treatments for depression, industry accounted for 29.8%, compared with 64.2% for academic and public sponsors.

The strategic opportunity is therefore collaborative. Pharma does not need to own every dataset or develop every new model. But it needs better ways to identify useful evidence, connect datasets, and translate biological signals into development decisions.

This also places greater importance on trial architecture. A study designed only around a near-term efficacy question may produce a useful endpoint, but a well-structured programme can generate clinical, biological, demographic, and longitudinal information with value beyond the original development milestone.

For World Mental Health Day in 2026, that is a useful perspective. The World Health Organisation’s theme this year is “Lived experiences heard: real voices, real change.”

This calls for people with lived experience to have a meaningful role in shaping mental health policies, services, and decisions.

Clinical Development has a parallel responsibility to collect evidence from patients that must be detailed enough to inform better decisions about the therapies they may ultimately receive.

At Pharmatica, we provide the Insights into the clinical evidence, data strategies, and development decisions shaping pharmaceutical R&D, connecting research with intelligence that leaders need to act with confidence.

Pharmatica: Insight. Connection. Impact.